Antiepileptic Drug Therapeutic Drug Monitoring
Therapeutic drug monitoring is recommended for phenytoin and carbamazepine, particularly when these drugs are used with enzyme-inducing or enzyme-inhibiting medications like rifampin or isoniazid. 1
Traditional Antiepileptic Drugs Requiring Routine Monitoring
The following "first-generation" antiepileptic drugs have well-established therapeutic ranges and benefit from routine therapeutic drug monitoring 2:
- Phenytoin - Requires monitoring due to nonlinear pharmacokinetics, narrow therapeutic index, and significant drug interactions 1
- Carbamazepine - Monitoring recommended due to enzyme induction properties and drug interactions 1
- Valproic acid - Benefits from monitoring, particularly in polytherapy and special populations 2, 3
- Phenobarbital - Monitoring useful given long half-life and potential for accumulation 2, 3
- Primidone - Requires monitoring as it is metabolized to phenobarbital 2
- Ethosuximide - Monitoring can guide dosing adjustments 2
Newer Antiepileptic Drugs with Monitoring Utility
Among second and third-generation antiepileptic drugs, therapeutic drug monitoring has more limited but specific utility 4, 2:
Strongest justification for monitoring:
- Lamotrigine - Monitoring recommended due to variable pharmacokinetics and serious rash risk 4, 2
- Oxcarbazepine - Monitoring of the active metabolite (MHD) can be useful 4, 2
- Zonisamide - Has established therapeutic ranges supporting monitoring 4, 2
- Stiripentol - Strongly protein-bound, candidate for free drug monitoring 4, 2
Moderate utility for monitoring:
- Levetiracetam - Generally does not require routine monitoring but may be useful in specific situations (pregnancy, renal impairment, suspected non-adherence) 2, 3
- Topiramate - Monitoring has limited but potential utility 4, 2
- Tiagabine - Strongly protein-bound, candidate for free drug monitoring 4, 2
Lower utility for monitoring:
- Gabapentin - Minimal benefit from routine monitoring 4, 2
- Pregabalin - Minimal benefit from routine monitoring 4, 2
- Vigabatrin - Lower utility for therapeutic drug monitoring 4, 2
Critical Drug Interaction Scenarios Requiring Monitoring
When rifampin is co-administered with antiepileptic drugs, therapeutic drug monitoring becomes essential 1:
- Rifampin induces metabolism of phenytoin and carbamazepine, potentially requiring dose increases 1
- Monitoring recommended with dose adjustments as needed 1
When isoniazid is co-administered with antiepileptic drugs, monitoring is critical 1:
- Isoniazid inhibits metabolism of phenytoin and carbamazepine, increasing risk of toxicity 1
- The combination of isoniazid and rifampin creates complex bidirectional effects on anticonvulsant levels 1
- Serum concentrations must be measured and doses adjusted accordingly 1
Important Caveats
Avoid enzyme-inducing antiepileptic drugs (phenytoin, phenobarbital, carbamazepine) when patients are receiving chemotherapy agents metabolized by cytochrome P450, as these can significantly reduce chemotherapy efficacy 5. Non-enzyme-inducing alternatives like levetiracetam should be used instead 5.
Remember that therapeutic ranges are guidelines, not absolute targets - individual therapeutic concentrations should be established for each patient based on clinical response 2, 6. The goal is seizure control without toxicity, which may occur at concentrations outside published ranges 2, 6.